Metropolis HealtQ1 FY27
Metropolis Healt Q1 FY27 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Price: ₹567P/E: 55.5Market Cap: ₹11.6K CrSector: Healthcare Services
Management growth scorecard
Revenue
Category 3
Margin
Category 1
Fundraise
N/A
Order
N/A
Capex
Yes
2 of 3 growth signals are positive.
Full analysisRevenue guidance
Category 3- →Metropolis expects a medium-term compounded annual growth rate (CAGR) of 14%-15% in revenue.
- →Patient volume growth is projected at 9%-10%, driven by network expansion into Tier-2 and Tier-3 towns and improved productivity of existing centers.
- →Network expansion continues with plans to add over 500 centers in the current financial year, deepening presence in 750 towns.
- →Balanced growth seen across mature centers and ramp-up in new centers.
- →B2C and B2B segments both contributing healthily, with B2C revenue growing 18% and B2B growing 15% year-on-year in Q1 FY 2027.
- →Growth supported by increased test volumes (+11% YoY), richer product mix, and improved realizations.
- →The company remains optimistic about broad-based and structural growth momentum across geographies, channels, and test categories.
Margin guidance
Category 1- →Management remains extremely optimistic about FY 2026-2027 growth and margin expansion.
- →Target to bring Core Diagnostics' EBITDA margin to 25% within 3-4 years; currently at ~8%.
- →TruHealth portfolio already aligned with company-level margins, contributing accretively to EBITDA.
- →Organic revenue growth guidance maintained at 14%-15% CAGR over medium term, largely driven by volume growth (9%-10%) and product mix.
- →EBITDA margin expected to expand by 100-150 basis points in the current financial year.
- →Medium-term target EBITDA margin is 27%-28% supported by operating leverage, productivity improvements, and cost optimization.
- →Strategy includes disciplined inorganic growth via value-accretive acquisitions.
- →Profit After Tax (PAT) grew 26% YoY in Q1 FY27; margins expanded by 90 bps to 12.6%.
- →Overall, sustainable, profitable growth with continued EBITDA and earnings expansion anticipated over the medium term.
3 more insights locked — sign up free to unlock
Fundraise plans
- →There is no mention of any current or future plans for fundraising through debt or equity in the provided text.
- →The management emphasizes organic growth and disciplined inorganic growth via strategic acquisitions at the right valuations.
- →The focus is on margin expansion, operational efficiency, and integrating recent acquisitions rather than raising new capital.
- →CAPEX for the current year is expected to be around INR 65 crores, similar to the prior year, funded from internal resources.
- →The company is cautious about acquisitions, focusing on earnings accretive deals and maintaining a disciplined valuation approach.
Order book
The document provided does not mention any information regarding Current or Expected Orderbook or Pending Orders for Metropolis Healthcare Limited.
Capex plans
Yes- Last year, Metropolis Healthcare spent around INR 65 crores on CAPEX for the entire Group, including acquired entities.
- CAPEX for the current year is expected to be in similar lines, i.e., approximately INR 65 crores.
- The Company is deepening presence in existing 750 towns rather than expanding beyond, limiting additional cost pressures.
- Lab expansion agenda has been on hold for the last five quarters, avoiding extra CAPEX from new labs.
- The focus remains on increasing productivity and operating leverage in existing centers.
- Strategic investments continue in bolt-on acquisitions with strong consumer brand, ethical practices, and positive unit economics—focused on disciplined valuations and accretive deals.
- Larger acquisitions may be considered if EPS accretive and value accretive to shareholders.
Overall, CAPEX is moderate and focused on operational efficiencies, network deepening, and selective strategic acquisitions.
How does Metropolis Healt rank vs peers in Healthcare Services?
Pro feature1Metropolis Healt
Rev 3Mar 1
See full Healthcare Services sector rankings
How does Metropolis Healt rank in Healthcare Services?
Compare Metropolis Healt against every Healthcare Services company (Q1 FY27) on revenue, margins and earnings-call signals.